Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab with platinum-pemetrexed for EGFR-mutant advanced non-small cell lung cancer after EGFR TKI progression
ACTRN12618001742268Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Apr 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of durvalumab, tremelimumab, pemetrexed, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by University of Sydney. Primary endpoint: Objective tumour response rate by RECIST 1.1. Started Apr 2019; status: completed.
02
Drugs
durvalumabtremelimumabpemetrexedcisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12618001742268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001742268.